| abstract |
REFERS TO TRIAZOLOPYRIDINE DERIVATIVES OF FORMULA (I), WHERE Q IS L, Laa O Lee; X IS C and Y IS N; or X IS N and Y IS C; G ES R4, R4aa, R4ee; WHERE R4 IS RENT, CYCLOALKYL, AMONG OTHERS; R4aa IS CYCLOALKYL OPTIONALLY SUBSTITUTED BY -OH, -OR6, -SR6, AMONG OTHERS; R4ee IS ALKYL, OPTIONALLY REPLACED BY HALOGEN, -OH, -OR6, AMONG OTHERS; L IS -ALKENYL- (W1) n, -CYCLOALKYL- (W1) n OR -ALKYL- (W2) n; Laa IS -ALKENYL- (W1) n OR -ALKYL- (W2aa) n; Read IS -ALQUENL- (W1ee) n, CYCLOALKYL- (W1) n OR -ALKYL- (W2ee) n; n IS 1 TO 3; W1 IS HALOGEN, -OH, -CO2R6, AMONG OTHERS; W1ee IS HALOGEN, -CO2R6, CYCLOALKYL, AMONG OTHERS; W2, W2aa, W2ee ARE EACH HALOGEN, -OH, ALKYL, AMONG OTHERS; WITH THE CONDITION THAT W2aa OR W2ee ARE NOT ONLY HALOGEN OR RENT; R3, R3a AND R3b ARE EACH H, HALOGEN, -NO2, AMONG OTHERS; R6 IS ALKYL, CYCLOALKYL, ARYL, OR HETEROARYL. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE FORMULA COMPOUND I AND TO A METHOD OF PREPARING A FORMULA COMPOUND (VII-F), WHICH INCLUDES IN REACTING A FORMULA HYDRAZIDE (VII-DPC) WITH A CARBONIC ACID (VII-DPC) DIISOPROPILETIAMINE IN THE PRESENCE OF A SOLVENT. SAID COMPOUND IS INHIBITOR OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE I, BEING USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS TYPE II DIABETES, OBESITY AND OSTEOPOROSIS |